Sanofi follows Lilly, Novo in cutting insulin prices
The french pharmaceutical firm mirrors its two rivals in announcing list price reductions on insulin.
By Ilena Peng, bloomberg
Sanofi will cut the US list price of two of its insulins, making it the third major producer of the diabetes medicine to recently slash prices.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Joe Biden applauds Novo Nordisk for insulin price reductions
For subscribers
.jpg&w=384&q=75)
